Fortrea Holdings (FTRE) Net Income (2022 - 2026)

Fortrea Holdings (FTRE) posted Net Income of -$23.6 million for Q1 2026, down 285.83% on a QoQ basis from $12.7 million in Q4 2024.

Fortrea Holdings (FTRE) Net Income (2022 - 2026) Analysis & Trends

Fortrea Holdings' Net Income history runs 4 years deep, the most recent figure standing at -$23.6 million for Q1 2026.

Quarterly Net Income changed N/A year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23.6 million (up 34.08% YoY) and the FY2024 annual result came in at -$57.0 million, down 976.92% from the prior year.
Net Income was -$23.6 million for Q1 2026 at Fortrea Holdings, down from $12.7 million in the prior quarter.
Across five years, Net Income topped out at $66.4 million in Q2 2022 and bottomed at -$39.1 million in Q2 2024.
A 4-year average of $3.3 million and a median of -$1.9 million in 2023 frame the typical range for Net Income.
Peak annual rise in Net Income reached 315.25% in 2024, while the deepest fall reached 774.14% in 2024.
Fortrea Holdings' Net Income stood at -$13.6 million in 2022, then surged by 56.62% to -$5.9 million in 2023, then jumped by 315.25% to $12.7 million in 2024, then plunged by 285.83% to -$23.6 million in 2026.
Business Quant data shows FTRE's Net Income at -$23.6 million in Q1 2026, $12.7 million in Q4 2024, and -$9.4 million in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Income (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-37.09 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	227.36 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-3.31 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	1.03 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	727.20 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-26.94 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	362.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-453.82 Mn
10	Fortrea Holdings	1.83 Bn	1.68 Bn	123.60 Mn	-23.60 Mn

Download Data